CA2846667C - Molecules de liaison au serpinf2 et procedes d'utilisation - Google Patents

Molecules de liaison au serpinf2 et procedes d'utilisation

Info

Publication number
CA2846667C
CA2846667C CA2846667A CA2846667A CA2846667C CA 2846667 C CA2846667 C CA 2846667C CA 2846667 A CA2846667 A CA 2846667A CA 2846667 A CA2846667 A CA 2846667A CA 2846667 C CA2846667 C CA 2846667C
Authority
CA
Canada
Prior art keywords
serpinf2
tpa
binding antibody
patient
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2846667A
Other languages
English (en)
Other versions
CA2846667A1 (fr
Inventor
Guy L. Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
TRANSLATIONAL SCIENCES Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRANSLATIONAL SCIENCES Inc filed Critical TRANSLATIONAL SCIENCES Inc
Priority claimed from PCT/US2012/053900 external-priority patent/WO2013036596A2/fr
Publication of CA2846667A1 publication Critical patent/CA2846667A1/fr
Application granted granted Critical
Publication of CA2846667C publication Critical patent/CA2846667C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des compositions et des procédés d'utilisation de molécules de liaison au serpinF2, dans la prévention et/ou la diminution de lésions des organes, de l'invalidité fonctionnelle ou de la mortalité chez un patient à risque, en raison de l'activité de la serpinF2 et/ou des activateurs plasminogènes sur les lésions tissulaires. L'invention porte en outre sur des compositions et des procédés d'utilisation de molécules de liaison au serpinF2 dans l'inhibition de l'hémorragie, de l'œdème et de l'apoptose. L'invention a également trait à des procédés de préparation de médicaments pour ces méthodes de traitement et de prévention.
CA2846667A 2011-09-06 2012-09-06 Molecules de liaison au serpinf2 et procedes d'utilisation Active CA2846667C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161531278P 2011-09-06 2011-09-06
US61/531,278 2011-09-06
PCT/US2012/053900 WO2013036596A2 (fr) 2011-09-06 2012-09-06 Molécules de liaison au serpinf2 et procédés d'utilisation

Publications (2)

Publication Number Publication Date
CA2846667A1 CA2846667A1 (fr) 2013-03-14
CA2846667C true CA2846667C (fr) 2026-04-07

Family

ID=

Similar Documents

Publication Publication Date Title
US20220298261A1 (en) Serpinf2-Binding Molecules and Method of Use Thereof
TWI684459B (zh) 一種治療動脈粥樣硬化及其併發症的方法
KR20160026905A (ko) 인자 ｘｉｉ 억제제 및 ｃ1-억제제를 이용한 병용 치료요법
Shamanaev et al. Mechanisms involved in hereditary angioedema with normal C1-inhibitor activity
TWI734798B (zh) 一種預防和治療肺纖維化的方法
TWI677348B (zh) 一種改善心臟病變的方法
Shamanaev et al. Factor XII structure–function relationships
US10676539B2 (en) Tissue plasminogen activator antibodies and methods of use
US20220184189A1 (en) Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
CN108463236A (zh) 一种预防或治疗放射性和化学性损伤的方法
CN106890320A (zh) 一种用于预防或治疗急性及慢性血栓的方法
CN106890325A (zh) 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
CN106890324A (zh) 一种预防和治疗糖尿病肾病的方法
JP7635223B2 (ja) 好中球細胞外トラップに関連する線維素溶解不全の診断方法
JP6624787B2 (ja) 脳内出血を治療するための組成物および方法
JP2009501188A (ja) 抗血小板療法で治療される患者における脳内出血（ＩＣＨ）後の出血増大及び／又は浮腫形成を予防又は軽減するための第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
US6911316B1 (en) Medical uses of scuPA/suPAR complex
US11078297B2 (en) Prophylaxis of thrombosis
CA2274477A1 (fr) Utilisations en medecine de complexe scupa/supar
Dávila-Rodrıguez Platelets are responsible for the accumulation of
HK1240124A1 (en) Method for preventing or treating diabetic nerve injury and related diseases
Munford Fulminant meningococcemia (purpura fulminans)
Factor In vivo roles of factor XII
Maat Natural pathways for factor XII activation: Implications for hereditary angioedema
Hjj The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability